2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Klatskin Tumor
2
Cholangiocarcinoma
2
Sarcoma, Kaposi
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Liver Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Hepatocellular
1
Acquired Immunodeficiency Syndrome
1
Interventions
Doxorubicin
16
Zidovudine
13
Vincristine
12
Bleomycin
11
Interferon alpha-2
6
Cyclophosphamide
6
Methotrexate
5
Liposomes
5
Leucovorin
5
Dexamethasone
5
tecogalan
4
sargramostim
4
Filgrastim
4
Etoposide
4
Cytarabine
4
Ritonavir
3
Nivolumab
3
Fluorouracil
3
pomalidomide
2
liposomal doxorubicin
2
interferon alfa-n1
2
Watchful Waiting
2
Valganciclovir
2
Tumor Necrosis Factor-alpha
2
Tobacco Use Cessation Devices
2
Thalidomide
2
Surveys and Questionnaires
2
Rituximab
2
Paclitaxel
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acquired Immunodeficiency Syndrome
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn